Apimeds Pharmaceuticals US Overview
Latest ROE for Apimeds Pharmaceuticals US: -54.65% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-54.65%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, APUS shows a ROE of -54.65%. That is below the sector sector average of -5.84%. Scroll down for historical charts and peer comparison views.
The its sector sector average ROE is about -5.84%. Apimeds Pharmaceuticals US is at -54.65%, which is lower that average. That is roughly 834.9% below the sector mean. Use the comparison chart on this page to see how APUS stacks up against individual peers as well.
Check the historical chart to see whether APUS's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Apimeds Pharmaceuticals US with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has Apimeds Pharmaceuticals US's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently -54.65%) with ownership activity and broader fundamentals.
